-
10:24:50 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

ENTA Stock News

08/08/22 4:03 PM
Nasdaq : ENTA
earningslow float
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2022. We look forward to initiating a Phase 2 study in the fourth quarter of this year,” said Jay R. Luly, Ph.D., President and Chief...
RHEA-AI
neutral
08/08/22 4:00 PM
Nasdaq : ENTA
managementlow float
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. Scott T. Rottinghaus, M.D., Senior Vice President and...
RHEA-AI
very positive
08/01/22 7:00 AM
Nasdaq : ENTA
conferencesearningslow float
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 after the U.S. market closes on August 8, 2022. A replay of the conference call will be...
RHEA-AI
neutral
07/29/22 7:00 AM
Nasdaq : ENTA
clinical trialcovid-19low float
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics of orally administered single ascending doses and multiple ascending doses of...
RHEA-AI
positive
06/08/22 7:00 AM
Nasdaq : ENTA
low float
Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’ s internal development program portfolio for hepatitis B virus and its out-licensing program portfolio for non-alcoholic steatohepatitis have been accepted...
RHEA-AI
neutral
05/18/22 4:01 PM
Nasdaq : ENTA
acquisitionlow float
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported topline results for RSVP, its Phase 2 b study evaluating EDP-938, a potent N-protein inhibitor, in otherwise healthy adults with community-acquired RSV. The effect on RSV RNA viral load is...
RHEA-AI
neutral
05/09/22 4:01 PM
Nasdaq : ENTA
earningslow float
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2022. “We had a strong start to 2022, making meaningful strides to advance our leadership in the development of therapeutics...
RHEA-AI
neutral
05/02/22 7:00 AM
Nasdaq : ENTA
conferencesearningslow float
Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2022 after the U.S. market closes on May 9, 2022. To participate in the live conference call,...
RHEA-AI
neutral